Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort

Rodrı́guez, Cristina; Elosua, Alfonso; Prieto, Carlos; Pérez, Ernesto; Irisarri, Rebeca; Campillo, Ana; Rubio, Saioa; Nantes, Óscar; Angós, Ramón; Zozaya, José Manuel

doi:10.1016/j.gastre.2020.11.009

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous publications have tried to identify predictive factors for colectomy. The paper by Rodriguez et al focused on the Navarra cohort, which included 174 patients and a follow-up period of 15.7 years, 8 patients required colectomy, 7 of which were on an emergency basis (megacolon, severe flare, treatment failure) [ 8 ]. The IBSEN cohort, which included patients from 4 regions in Norway, reported a 9.8% colectomy rate at 10 years among patients with extensive disease, need for corticosteroids, and significant inflammation (CRP >30mg/dl levels) at diagnosis [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab

Ciortescu,

Nemteanu,

Gheorghe

2023

Arch Clin Cases

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic inflammatory condition, with a relapsing-remitting course. The case presented poses some valid questions regarding short-term and long-term management of patients with UC, and if the outcome (colectomy) could have been delayed or even prevented. Rectal bleeding is a cardinal symptom in patients with UC and it occurs among all patients during active disease. Massive rectal bleeding is an uncommon, but serious, complication of UC accounting for 0.1-1.4% of admissions. It is, nonetheless, noteworthy that instances of acute significant lower gastrointestinal bleeding accompanied by hemodynamic instability are infrequent. The rate of colectomy appears to be positively impacted by biological treatment. However, a refractory condition is still the primary reason for surgery, indicating a pressing need for new treatment approaches. Here we present the case of a young male patient who developed massive rectal bleeding and underwent emergent colectomy with ileostomy while having clinical and biological remission (normal calprotectin levels) at week 10 of Vedolizumab treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab

Ciortescu,

Nemteanu,

Gheorghe

2023

Arch Clin Cases

View full text Add to dashboard Cite

show abstract

“…This has been noted in United Kingdom, Italy, Sweden, Norway and Denmark. 27,[36][37][38][39][40][41] However, caution should be taken when attempting direct comparison of surgical rates across time and between countries due to the lack of concomitant data on disease severity and inter-country differences in treatment practice and availability of novel medication. 42 Furthermore, many countries have not reported surgical trend data over time, such as in Spain and Belgium.…”

Section: Surgical and Hospitalisation Ratesmentioning

confidence: 99%

Crossing barriers: the burden of inflammatory bowel disease across Western Europe

Kumar,

Yassin,

Marley

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

An estimated 2.5–3 million individuals (0.4%) in Europe are affected by inflammatory bowel disease (IBD). Whilst incidence rates for IBD are stabilising across Europe, the prevalence is rising and subsequently resulting in a significant cost to the healthcare system of an estimated 4.6–5.6 billion euros per year. Hospitalisation and surgical resection rates are generally on a downward trend, which is contrary to the rising cost of novel medication. This signifies a large part of healthcare cost and burden. Despite publicly funded healthcare systems in most European countries, there is still wide variation in how patients receive and/or pay for biologic medication. This review will provide an overview and discuss the different healthcare systems within Western Europe and the barriers that affect overall management of a changing IBD landscape, including differences to hospitalisation and surgical rates, access to medication and clinical trial participation and recruitment. This review will also discuss the importance of standardising IBD management to attain high-quality care for all patients with IBD.

show abstract

Colectomy rate in ulcerative colitis 15 years after diagnosis: Results from the 2001-2003 Navarra cohort

Cited by 2 publications

References 20 publications

Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab

Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab

Crossing barriers: the burden of inflammatory bowel disease across Western Europe

Contact Info

Product

Resources

About